First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene - Phase II trial.
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Carboplatin (Primary) ; Gefitinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
- 25 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 May 2011 New trial record